Vaginitis: Review on Drug Resistance

Curr Drug Targets. 2020;21(16):1672-1686. doi: 10.2174/1389450121666200804112340.

Abstract

Female genital tract infections have a high incidence among different age groups and represent an important impact on public health. Among them, vaginitis refers to inflammation of the vulva and/or vagina due to the presence of pathogens that cause trichomoniasis, bacterial vaginosis, and vulvovaginal candidiasis. Several discomforts are associated with these infections, as well as pregnancy complications and the facilitation of HIV transmission and acquisition. The increasing resistance of microorganisms to drugs used in therapy is remarkable, since women report the recurrence of these infections and associated comorbidities. Different resistant mechanisms already described for the drugs used in the therapy against Trichomonas vaginalis, Candida spp., and Gardnerella vaginalis, as well as aspects related to pathogenesis and treatment, are discussed in this review. This study aims to contribute to drug design, avoiding therapy ineffectiveness due to drug resistance. Effective alternative therapies to treat vaginitis will reduce the recurrence of infections and, consequently, the high costs generated in the health system, improving women's well-being.

Keywords: Candida spp; Gardnerella vaginalis; Trichomonas vaginalis; Vaginitis; drug target; resistance.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Anti-Infective Agents / pharmacology
  • Anti-Infective Agents / therapeutic use
  • Candidiasis, Vulvovaginal / drug therapy
  • Candidiasis, Vulvovaginal / microbiology
  • Drug Resistance, Microbial / physiology*
  • Female
  • Humans
  • Trichomonas Infections / drug therapy
  • Trichomonas Infections / microbiology
  • Trichomonas vaginalis / drug effects
  • Trichomonas vaginalis / microbiology
  • Vaginitis / drug therapy*
  • Vaginitis / microbiology

Substances

  • Anti-Infective Agents